HomeCompareSPYD vs EW

SPYD vs EW: Dividend Comparison 2026

SPYD yields 4.41% · EW yields 2.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPYD wins by $3.2K in total portfolio value
10 years
SPYD
SPYD
● Live price
4.41%
Share price
$45.11
Annual div
$1.99
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.7K
Annual income
$584.62
Full SPYD calculator →
EW
EW
● Live price
2.52%
Share price
$79.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.4K
Annual income
$295.93
Full EW calculator →

Portfolio growth — SPYD vs EW

📍 SPYD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPYDEW
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPYD + EW cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPYD pays
EW pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPYD
Annual income on $10K today (after 15% tax)
$374.62/yr
After 10yr DRIP, annual income (after tax)
$496.93/yr
EW
Annual income on $10K today (after 15% tax)
$213.84/yr
After 10yr DRIP, annual income (after tax)
$251.54/yr
At 15% tax rate, SPYD beats the other by $245.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPYD + EW for your $10,000?

SPYD: 50%EW: 50%
100% EW50/50100% SPYD
Portfolio after 10yr
$25.1K
Annual income
$440.27/yr
Blended yield
1.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EW right now

SPYD
No analyst data
EW
Analyst Ratings
32
Buy
16
Hold
Consensus: Buy
Price Target
$96.38
+21.2% upside vs current
Range: $87.00 — $110.00
Altman Z
10.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPYD buys
0
EW buys
0
No recent congressional trades found for SPYD or EW in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPYDEW
Forward yield4.41%2.52%
Annual dividend / share$1.99$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$26.7K$23.4K
Annual income after 10y$584.62$295.93
Total dividends collected$5.2K$2.8K
Payment frequencyquarterlyquarterly
SectorETFHealthcare

Year-by-year: SPYD vs EW ($10,000, DRIP)

YearSPYD PortfolioSPYD Income/yrEW PortfolioEW Income/yrGap
1← crossover$11,141$440.73$10,952$251.57+$189.00SPYD
2$12,379$458.88$11,976$257.49+$403.00SPYD
3$13,723$476.54$13,077$263.14+$646.00SPYD
4$15,177$493.69$14,261$268.55+$916.00SPYD
5$16,750$510.29$15,533$273.70+$1.2KSPYD
6$18,448$526.32$16,899$278.61+$1.5KSPYD
7$20,281$541.78$18,365$283.28+$1.9KSPYD
8$22,258$556.65$19,938$287.72+$2.3KSPYD
9$24,387$570.93$21,626$291.93+$2.8KSPYD
10$26,678$584.62$23,436$295.93+$3.2KSPYD

SPYD vs EW: Complete Analysis 2026

SPYDETF

The State Street SPDR Portfolio S&P 500 High Dividend ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P 500 High Dividend Index (the "Index")A low cost ETF that seeks to provide a high level of dividend income and the opportunity for capital appreciationThe Index is designed to measure the performance of the top 80 high dividend-yielding companies within the S&P 500 IndexOne of the low cost core State Street SPDR Portfolio ETFs, a suite of portfolio building blocks designed to provide broad, diversified exposure to core asset classes

Full SPYD Calculator →

EWHealthcare

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Full EW Calculator →
📬

Get this SPYD vs EW comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPYD vs SCHDSPYD vs JEPISPYD vs OSPYD vs KOSPYD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.